TNF Inhibitors in Psoriasis: A Review.
Semin Cutan Med Surg
; 34(2 Suppl): S37-9, 2015 Mar.
Article
em En
| MEDLINE
| ID: mdl-26625254
ABSTRACT
Adalimumab, etanercept, and infliximab are tumor necrosis factor (TNF) inhibitors that are currently approved by the US Food and Drug Administration for the treatment of moderate to severe psoriasis. The availability of these biologic agents established a new benchmark in the treatment of psoriasis that requires systemic therapy to control psoriasis signs and symptoms. Although a number of other biologic agents and small molecules have been approved recently, TNF inhibitors remain a cornerstone of psoriasis therapy. Semin Cutan Med Surg 34(supp2)S37-S39 © 2015 published by Frontline Medical Communications.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Idioma:
En
Ano de publicação:
2015
Tipo de documento:
Article